BR9700768A - Cepan tw928 de streptococcus equi cultura microbilóbica pura compreemdido uma bactéria vacina viva para combater infecção por streptococcus em cavalos processo par a preparação da mesma e uso da cepa tw928 de streptococcus equi - Google Patents

Cepan tw928 de streptococcus equi cultura microbilóbica pura compreemdido uma bactéria vacina viva para combater infecção por streptococcus em cavalos processo par a preparação da mesma e uso da cepa tw928 de streptococcus equi

Info

Publication number
BR9700768A
BR9700768A BR9700768A BR9700768A BR9700768A BR 9700768 A BR9700768 A BR 9700768A BR 9700768 A BR9700768 A BR 9700768A BR 9700768 A BR9700768 A BR 9700768A BR 9700768 A BR9700768 A BR 9700768A
Authority
BR
Brazil
Prior art keywords
streptococcus
streptococcus equi
strain
horses
microbilobic
Prior art date
Application number
BR9700768A
Other languages
English (en)
Other versions
BRPI9700768B1 (pt
BRPI9700768B8 (pt
Inventor
Orla Mary Hartford
Timothy James Foster
Antonius Arnodus Christ Jacobs
Original Assignee
Trinity College Dublin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8223610&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9700768(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Trinity College Dublin filed Critical Trinity College Dublin
Publication of BR9700768A publication Critical patent/BR9700768A/pt
Publication of BRPI9700768B1 publication Critical patent/BRPI9700768B1/pt
Publication of BRPI9700768B8 publication Critical patent/BRPI9700768B8/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/09Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092Streptococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • C12N1/205Bacterial isolates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12RINDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00Microorganisms ; Processes using microorganisms
    • C12R2001/01Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/46Streptococcus ; Enterococcus; Lactococcus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
BRPI9700768A 1996-01-25 1997-01-24 vacina viva para combater infecção por streptococcus em cavalos. BRPI9700768B8 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96200171 1996-01-25

Publications (3)

Publication Number Publication Date
BR9700768A true BR9700768A (pt) 1998-11-03
BRPI9700768B1 BRPI9700768B1 (pt) 2008-11-04
BRPI9700768B8 BRPI9700768B8 (pt) 2016-11-16

Family

ID=8223610

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9700768A BRPI9700768B8 (pt) 1996-01-25 1997-01-24 vacina viva para combater infecção por streptococcus em cavalos.

Country Status (16)

Country Link
US (1) US5895654A (pt)
EP (1) EP0786518B1 (pt)
JP (1) JP3911058B2 (pt)
AT (1) ATE219511T1 (pt)
AU (1) AU703942B2 (pt)
BR (1) BRPI9700768B8 (pt)
CA (1) CA2195935C (pt)
CZ (1) CZ289530B6 (pt)
DE (1) DE69713408T2 (pt)
DK (1) DK0786518T3 (pt)
ES (1) ES2179261T3 (pt)
NZ (1) NZ314091A (pt)
PL (1) PL187163B1 (pt)
PT (1) PT786518E (pt)
RU (1) RU2194752C2 (pt)
ZA (1) ZA97452B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6682745B1 (en) 1998-07-28 2004-01-27 Christiaan Antonius Arnoldus Jacobs Use of bacterium for manufacture of a vaccine
CA2243730C (en) * 1997-07-29 2009-12-22 Akzo Nobel N.V. Streptococcus equi vaccine
US20080050367A1 (en) * 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
WO1999027949A1 (en) * 1997-12-03 1999-06-10 Brigham And Women's Hospital METHOD OF SUPPRESSING β-AMYLOID-RELATED CHANGES IN ALZHEIMER'S DISEASE
FR2775601B1 (fr) * 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
EP1023903B1 (en) * 1999-01-26 2004-01-14 Akzo Nobel N.V. Use of life attenuated bacteria for the manufacture of a submucosal vaccine
US6541458B1 (en) 1999-07-16 2003-04-01 Merial Feline calicivirus genes and vaccines in particular recombinant vaccines
FR2796397B1 (fr) * 1999-07-16 2006-09-01 Merial Sas Genes de calicivirus felin et vaccins notamment vaccins recombines
US8889112B2 (en) * 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
US20020082288A1 (en) * 1999-09-16 2002-06-27 Gerald Horn Ophthalmic formulations comprising an imidazoline
US6420407B1 (en) 1999-09-16 2002-07-16 Gerald Horn Ophthalmic formulation which modulates dilation
US6730065B1 (en) 2000-09-15 2004-05-04 Ocularis Pharma, Inc. Night vision composition
US20060211753A1 (en) * 2000-11-03 2006-09-21 Ocularis Pharma, Inc. Method and composition which reduces stimulation of muscles which dilate the eye
GB2370770B (en) * 2001-01-03 2005-06-01 Simon Connolly Uses of Streptococcus Vaccines
EP1838348B1 (en) 2004-12-15 2013-06-26 Janssen Alzheimer Immunotherapy Humanized amyloid beta antibodies for use in improving cognition
US8784810B2 (en) * 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
JP5889529B2 (ja) * 2007-07-27 2016-03-22 ヤンセン・サイエンシズ・アイルランド・ユーシー アミロイド原性疾患の処置
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
GB0801326D0 (en) 2008-01-24 2008-03-05 Animal Health Trust Vaccines
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
GB201209014D0 (en) * 2012-05-22 2012-07-04 Moredun Res Inst Vaccine
WO2014121028A1 (en) 2013-02-01 2014-08-07 Ocularis Pharma, Llc Methods and compositions for daily ophthalmic administration of phentolamine to improve visual performance
WO2014121027A1 (en) 2013-02-01 2014-08-07 Oculars Pharma, Llc Aqueous ophthalmic solutions of phentolamine and medical uses thereof
EP3057613A1 (en) 2013-10-17 2016-08-24 Zoetis Services LLC Methods and compositions for treatment of s. equi infection
EP2949340A1 (en) * 2014-05-30 2015-12-02 IDT Biologika GmbH Vaccine composition against Streptococcus suis infection
GB2564481B (en) * 2017-07-14 2019-10-23 4D Pharma Leon S L U Process
WO2020087021A1 (en) 2018-10-26 2020-04-30 Ocuphire Pharma, Inc. Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders
CN115368310A (zh) 2021-05-18 2022-11-22 奥库菲尔医药公司 合成甲磺酸酚妥拉明的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4110433A (en) * 1976-04-23 1978-08-29 Philips Roxane, Inc. Equine rhinopneumonitis virus
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4582798A (en) * 1984-11-23 1986-04-15 Miles Laboratories, Inc. Preparation and use of enzyme-detergent extracted Streptococcus equi vaccine
AR241545A1 (es) * 1985-07-12 1992-08-31 Cornell Res Foundation Inc Un metodo para preparar una cepa de s. equi avirulenta a.t.c.c. 53186 para equinos.
US4788059A (en) * 1985-07-15 1988-11-29 Coopers Animal Health, Inc. Equine strangles vaccine and the method of preparing and using the same
IL86583A0 (en) * 1987-06-04 1988-11-15 Molecular Eng Ass Vaccine containing a derivative of a microbe and method for the production thereof
US5468485A (en) * 1987-06-04 1995-11-21 Washington University Avirulent microbes and uses therefor
US5294441A (en) * 1987-06-04 1994-03-15 Washington University Avirulent microbes and uses therefor: salmonella typhi
WO1989003427A1 (en) * 1987-10-07 1989-04-20 Washington University A method of maintaining a desired recombinant gene in a genetic population of cells
DE69419966T2 (de) * 1993-05-17 2000-01-20 Akzo Nobel N.V., Arnheim/Arnhem Impstoff gegen Streptococcus suis-Infektion
ATE178654T1 (de) * 1993-12-20 1999-04-15 Akzo Nobel Nv Impstoff zum schutze von pferden gegen pferdeherpesvirus-infektionen

Also Published As

Publication number Publication date
PT786518E (pt) 2002-10-31
PL318095A1 (en) 1997-08-04
CA2195935A1 (en) 1997-07-26
RU2194752C2 (ru) 2002-12-20
JP3911058B2 (ja) 2007-05-09
NZ314091A (en) 1998-06-26
CA2195935C (en) 2006-06-27
ATE219511T1 (de) 2002-07-15
DE69713408T2 (de) 2002-11-21
AU1234697A (en) 1997-08-07
US5895654A (en) 1999-04-20
BRPI9700768B1 (pt) 2008-11-04
DK0786518T3 (da) 2002-09-16
EP0786518B1 (en) 2002-06-19
BRPI9700768B8 (pt) 2016-11-16
CZ21497A3 (cs) 1998-03-18
ES2179261T3 (es) 2003-01-16
PL187163B1 (pl) 2004-05-31
EP0786518A1 (en) 1997-07-30
DE69713408D1 (de) 2002-07-25
JPH09215492A (ja) 1997-08-19
ZA97452B (en) 1997-08-15
AU703942B2 (en) 1999-04-01
CZ289530B6 (cs) 2002-02-13

Similar Documents

Publication Publication Date Title
BR9700768A (pt) Cepan tw928 de streptococcus equi cultura microbilóbica pura compreemdido uma bactéria vacina viva para combater infecção por streptococcus em cavalos processo par a preparação da mesma e uso da cepa tw928 de streptococcus equi
CY1105389T1 (el) Hpv-e7 ως αγωγη εναντι του ιου θηλωματων ανθρωπου
LU91778I2 (fr) Menveo - vaccin méningococcique des groupes A,C, W135 et Y conjugué.
PT1203817E (pt) Compostos e metodos para imunoterapia e le diagnostic de tuberculose
DE60036698D1 (de) Chlamydia-antigene und entsprechende dna-fragmente und deren verwendungen
IL136125A0 (en) Antigenic group b streptococcus type ii and type iii polysaccharide fragments having a 2, 5-anhydro-d-mannose terminal structure and conjugate vaccine thereof
CA2145397A1 (en) Group b streptococcus type ii and type v polysaccharide-protein conjugate vaccines
GR3035135T3 (en) Poultry vaccine containing infections bronchitis virus serotype 4/91.
CA2022420A1 (en) Escherichia coli vaccine
ES2137310T3 (es) Vacuna contra una infeccion por streptococcus suis.
HK1004677A1 (en) Antigenic preparation for treatment or prevention of helicobacter infection
BR0316395A (pt) Vacina atenuada viva contra pleuropneumonia porcina
EA200100700A1 (ru) Гены и белки и их применение
WO2001078787A3 (en) Lipopolysaccharide-conjugate vaccine for sepsis treatment
CA2243730A1 (en) Streptococcus equi vaccine
BRPI0508660A (pt) composição de vacina eficaz na prevenção ou melhora da infecção por vìrus da doença bursal infecciosa; composição de vacina; isolado antigênico do vìrus da doença bursal infecciosa; e método para induzir proteção contra infecção do vìrus da doença bursal infecciosa
AR009650A1 (es) Mycoplasma synoviae atenuado vivo, su uso, un cultivo microbiologico que lo comprende, una vacuna bacteriana atenuada viva para la proteccion de las aves de corral contra la infeccion por mycoplasma synoviae y un metodo para preparar dicha vacuna.
EP2364726A3 (en) Vaccine against neisseria infection
NO20013101L (no) Ytre overflateproteiner, deres gener og deres anvendelse
NZ512308A (en) Chlamydia antigens and corresponding DNA fragments and uses thereof
RU96116250A (ru) Штамм pestivirus, используемый для изготовления лапинизированной вирус вакцины против классической чумы свиней

Legal Events

Date Code Title Description
FB34 Technical and formal requirements: requirement - article 34 of industrial property law
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/11/2008, OBSERVADAS AS CONDICOES LEGAIS.

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI-52400.061557/2013 ORIGEM: JUIZO DA 013A VARA FEDERAL DO RIO DE JANEIRO PROCESSO NO 0132378-91.2013.4.02.5101 ACAO DE NULIDADE DAS PATENTES SUBMETIDAS AO MAILBOX (ART. 229, PARAGRAFO UNICO DA LPI); ALTERNATIVAMENTE, A DECRETACAO DA NULIDADE PARCIAL PARA CORRECAO DO PRAZO DE VIGENCIA; SUBSIDIARIAMENTE, CASO SE ENTENDA NAO SER O CASO DE NULIDADE, A CORRECAO DO ATO ADMINISTRATIVO PARA ADEQUACAO DA VIGENCIA DAS PATENTES. AUTOR: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI REU: RECKITT BENCKISER HEALTHCARE (UK) LIMITED, SANOFI-AVERTIS, SEPSICURE, L.L.C, THE AUSTRALIAN NATIONAL UNIVERSITY, THE PROVOST FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY UNDIVIDED TRINITY OF QUEEN ELIZA

B19A Notification of judicial decision: notification of judicial decision

Free format text: INPI-52400.129576/2014 SECAO JUDICIARIA DO RIO DE JANEIRO 13A VARA FEDERAL PROCESSO: NO0002752-82.2014.4.02.5101 AUTOR: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL INPI E OUTRO REU: THE PROVOST FELLOWS AND SCHOLARS OF THE HOLY UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN E OUTRO DECISAO: ANTE A CERTEZA DO DIREITO E A PROVA INEQUIVOCA DOS AUTOS, CONCEDO A ANTECIPACAO DOS EFEITOS DA TUTELA, A FIM DE DETERMINAR A IMEDIATA READEQUACAO DO PRAZO DE VIGENCIA DA PATENTE PI 9700768-4 PARA VINTE ANOS CONTADOS A PARTIR DO RESPECTIVO DEPOSITO, NOS TERMOS DO PARAGRAFO UNICO DO ART.229 C/C O CAPUT DO ART. 40 DA LPI, OU SEJA, COM PRAZO DE VIGENCIA ATE 24/01/2017.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE A RPI 1974 DE 04/11/2008, QUANTO AO PRAZO DE VALIDADE CONFORME DECISAO DA 13A VARA FEDERAL DO RIO DE JANEIRO, PROCESSO: 0002752-82.2014.4.02.5101 (2014.51.01.002752-7 - INPI 52400.129576/2014-52

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 24.01.2017